Vitreoretinal traction - Symptoms, Causes, Treatment & Prevention

Overview

Vitreoretinal traction (VRT) describes a condition in which the vitreous gel that fills the eye pulls on the retina, the light‑sensing tissue at the back of the eye. When this pulling force becomes abnormal, it can distort or detach the retina, leading to visual disturbances and, if left untreated, permanent vision loss.

VRT is not a single disease but a mechanical phenomenon that can accompany several ocular disorders, the most common being epiretinal membrane (ERM), vitreomacular traction (VMT) syndrome, and proliferative diabetic retinopathy. It typically affects adults over the age of 50, but younger patients with diabetes, high myopia, or a history of eye surgery may also develop traction.

Prevalence: Large‑scale studies estimate that clinically significant vitreomacular traction occurs in roughly 0.1–0.4 % of people over 40 years old, while epiretinal membranes (the most frequent cause of VRT) are seen in up to 20 % of individuals >70 years (source: NIH – Ocular Epidemiology Review, 2015).

Symptoms

Because VRT affects the central retina, symptoms are often subtle at first and may progress over weeks to months. Common complaints include:

• Metamorphopsia – distortion of straight lines (e.g., appearing wavy or bent).
• Central vision blurring – difficulty reading or recognizing faces.
• Floaters – dark specks that move with eye motion, caused by vitreous debris.
• Micropsia or macropsia – objects appear smaller or larger than they are.
• Photopsia – brief flashes of light, especially in peripheral vision.
• Reduced contrast sensitivity – colors and shades look washed out.
• Difficulty with near tasks – such as sewing, using a smartphone, or reading a book.
• Pain or pressure – rare, usually only when traction leads to retinal tear or detachment.

If any symptom suddenly worsens or is accompanied by new flashes or a curtain‑like shadow, immediate medical attention is required (see “When to Seek Emergency Care”).

Causes and Risk Factors

Primary mechanisms

VRT results from abnormal adhesion between the vitreous and the retina. The most common pathways are:

1. Age‑related vitreous liquefaction (syneresis) – As we age, the collagen‑hyaluronic acid matrix of the vitreous becomes more liquid, creating pockets of traction.
2. Epiretinal membrane formation – Cellular proliferation on the inner retinal surface creates a fibrocellular sheet that contracts and pulls on the retina.
3. Vitreomacular traction (VMT) syndrome – Incomplete separation of the vitreous from the macula leaves focal adhesions that tug on retinal tissue.
4. Inflammatory or proliferative diseases – Diabetic retinopathy, retinal vein occlusion, or uveitis can stimulate fibrovascular growth that exerts traction.
5. Ocular trauma or surgery – Cataract extraction, vitrectomy, or penetrating injuries may alter vitreoretinal interfaces.

Risk factors

• Age – Risk rises sharply after age 50.
• High myopia (>-6 D) – Stretched sclera predisposes to early vitreous detachment.
• Diabetes mellitus – Especially with proliferative retinopathy.
• Previous retinal surgery or laser photocoagulation.
• Family history of epiretinal membranes.
• Systemic connective‑tissue disorders such as Marfan or Ehlers‑Danlos syndromes.

Diagnosis

Accurate diagnosis relies on a combination of patient history, visual‑function testing, and advanced imaging.

Clinical examination

• Visual acuity test – Determines the impact on central vision.
• A‑scan or B‑scan ultrasonography – Useful when media opacity (cataract, vitreous hemorrhage) limits view.
• Dilated fundus examination – Performed with a binocular indirect ophthalmoscope or slit‑lamp biomicroscopy to directly visualize traction, membranes, or retinal tears.

Imaging modalities

1. Optical Coherence Tomography (OCT) – The gold standard. High‑resolution cross‑sectional images reveal the exact site and severity of vitreoretinal adhesion, macular thickness, and presence of an epiretinal membrane.
2. Fundus photography – Documents baseline appearance and monitors progression.
3. Fluorescein angiography (FA) – Reserved for cases with suspected vascular leakage (e.g., diabetic retinopathy) and can highlight areas of ischemia.
4. Wide‑field imaging – Helpful when peripheral traction or tears are suspected.

Diagnosis is usually confirmed by an ophthalmologist or retina specialist. Screening is recommended for patients with known risk factors, especially diabetics undergoing routine eye exams.

Treatment Options

The therapeutic goal is to relieve traction, preserve or improve vision, and prevent retinal detachment. Management ranges from observation to minimally invasive procedures.

Observation

In cases with mild traction and stable vision, regular monitoring (every 3–6 months) with OCT may be sufficient. Many epiretinal membranes remain quiescent for years.

Pharmacologic therapy

• Intravitreal anti‑VEGF agents (e.g., ranibizumab, aflibercept) – Primarily used when VRT coexists with macular edema from diabetic retinopathy or age‑related macular degeneration. They can reduce swelling and indirectly lessen traction.
• Corticosteroid injections – Dexamethasone implants may be considered for inflammatory‑driven traction, though evidence is limited.

Medication alone rarely resolves the mechanical pull; they are adjuncts to surgical therapy.

Surgical interventions

1. Pars plana vitrectomy (PPV) – The mainstay procedure. The surgeon removes the vitreous gel, releases adhesions, and peels any epiretinal membrane. Modern 23‑ or 25‑gauge micro‑instruments allow suture‑less, fast recovery.
2. En‑face membrane peeling – Performed during PPV; special dyes (indocyanine‑green or trypan blue) highlight the membrane for safe removal.
3. Gas or silicone oil tamponade – Used selectively to flatten the retina after traction release, especially if a retinal break is present.
4. Pharmacologic vitreolysis – Ocriplasmin (Jetrea) is an FDA‑approved enzymatic agent that can dissolve vitreoretinal adhesions in select VMT cases without surgery. Success rates vary (≈ 30–40 % complete release) and are lower in eyes with thick membranes or high myopia.

Post‑operative care

• Head positioning (face‑down) for 1–3 days if gas tamponade is used.
• Topical antibiotics and steroids to prevent infection and inflammation.
• Follow‑up OCT at 1 month and then periodically to assess retinal re‑attachment and visual recovery.

Living with Vitreoretinal Traction

Even after successful treatment, patients may need to adapt daily habits to protect their eyes and maximize visual function.

Practical tips

• Regular eye exams – At least annually, or more often if you have diabetes or have undergone retinal surgery.
• Protective eyewear – Wear sunglasses with UV protection and safety goggles during high‑impact activities.
• Avoid high‑impact sports – Contact sports (e.g., basketball, boxing) increase the risk of traumatic retinal tears.
• Manage systemic conditions – Keep blood glucose, blood pressure, and cholesterol within target ranges to reduce diabetic retinopathy progression.
• Use appropriate visual aids – Magnifiers, high‑contrast reading glasses, or screen‑enlargement software can improve near‑task performance.
• Maintain a healthy lifestyle – Balanced diet rich in omega‑3 fatty acids, leafy greens, and antioxidants supports retinal health.
• Stay hydrated and limit caffeine – Excessive caffeine may exacerbate vitreous liquefaction in susceptible individuals.

Prevention

While age‑related changes cannot be stopped, several strategies can lower the likelihood of developing problematic VRT.

• Control diabetes – Tight glycemic control reduces proliferative retinal changes (CDC, 2024).
• Regular retinal screening – Early detection of epiretinal membranes or vitreomacular traction allows timely intervention.
• Quit smoking – Smoking accelerates ocular vascular damage.
• Protect eyes from trauma – Use safety glasses when working with tools or playing sports.
• Limit high‑myopia progression – Orthokeratology or low‑dose atropine in children can reduce severe myopic stretch later in life.

Complications

If vitreoretinal traction is not addressed, the mechanical forces can lead to serious sequelae:

• Full‑thickness retinal tear – The retina can be pulled apart, creating a pathway for fluid to accumulate under it.
• Rhegmatogenous retinal detachment (RRD) – Fluid migrates through a retinal break, separating the retina from the underlying pigment epithelium; this is an ophthalmic emergency.
• Macular edema – Persistent traction causes fluid accumulation, worsening central vision.
• Permanent visual loss – Chronic distortion or detachment can lead to irreversible photoreceptor damage.
• Secondary glaucoma – In rare cases, postoperative inflammation or silicone oil tamponade can raise intraocular pressure.

When to Seek Emergency Care

---

**References** (selected)

• Mayo Clinic. “Vitreomacular traction syndrome.” 2023. Link
• National Eye Institute (NEI). “Epiretinal membrane.” 2022. Link
• American Academy of Ophthalmology. “Ocriplasmin for vitreomacular traction.” 2021. Link
• Centers for Disease Control and Prevention. “Diabetes and eye disease.” 2024. Link
• World Health Organization. “Blindness and visual impairment.” 2023. Link
• Cleveland Clinic. “Retinal detachment – symptoms and treatment.” 2023. Link